Remedy Plan Therapeutics

Company profile

Remedy Plan Therapeutics company profile

Remedy Plan Therapeutics is a pre-clinical-stage company developing small molecule therapeutics to halt tumor growth and disrupt the cancer stem cells that cause metastasis. Our approach is to develop effective, non-toxic treatments that target the dangerous embryonic properties of cancer stem cells, which form the basis for cancer growth, spread, and resistance to chemotherapy. Remedy Plan is positioned to deliver one first-in-class drug candidate for Phase I clinical development approximately 15 months after Series A funding Remedy Plan's proprietary drug screening platform identifies drug candidates that differentiate cancer stem cells, disrupt proliferation, and inhibit formation of new tumors. From the initial screen of 40,000 drug components, a lead candidate is currently undergoing optimization and mechanism of action studies in preparation for Phase I clinical trials. With the second screen of over 100,000 drug components completed, Remedy Plan aims to have at least two drugs in clinical development by 2020.